|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-9-5
|
|
pubmed:abstractText |
Phase I/II studies of 4 weeks duration have confirmed the ALT lowering effect of glycyrrhizin in Western chronic hepatitis C patients. Our aim was to determine the dose frequency of glycyrrhizin required to maintain the ALT response beyond 4 weeks and evaluate its effect on liver histology and quality of life.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0168-8278
|
|
pubmed:author |
pubmed-author:BrouwerJohannes TJT,
pubmed-author:GerkenGuidoG,
pubmed-author:HansenBettina EBE,
pubmed-author:HuberRomanR,
pubmed-author:Kullak-UblickGerd AGA,
pubmed-author:LaggingMartinM,
pubmed-author:NevensFrederikF,
pubmed-author:OrlentHansH,
pubmed-author:SchalmSolko WSW,
pubmed-author:TielemansWanda C MWC,
pubmed-author:WestinJohanJ,
pubmed-author:WillemsMarcM,
pubmed-author:ZeuzemStefanS,
pubmed-author:ZondervanPieter EPE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
45
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
539-46
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16905220-Adolescent,
pubmed-meshheading:16905220-Adult,
pubmed-meshheading:16905220-Aged,
pubmed-meshheading:16905220-Alanine Transaminase,
pubmed-meshheading:16905220-Antiviral Agents,
pubmed-meshheading:16905220-Drug Monitoring,
pubmed-meshheading:16905220-Female,
pubmed-meshheading:16905220-Glycyrrhizic Acid,
pubmed-meshheading:16905220-Hepacivirus,
pubmed-meshheading:16905220-Hepatitis C, Chronic,
pubmed-meshheading:16905220-Humans,
pubmed-meshheading:16905220-Male,
pubmed-meshheading:16905220-Middle Aged,
pubmed-meshheading:16905220-Quality of Life,
pubmed-meshheading:16905220-RNA, Viral,
pubmed-meshheading:16905220-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
|
|
pubmed:affiliation |
Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
